Resubmission of H2 and FY25 audited financial results

Revenue Growth 20pctPat Growth 25pctResults RestatedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.1%Reaction day

₹344.50

prior close

₹319.95

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-7.5% vs market

Pharmaceuticals peers, median of 174sector-0.3%-6.8% vs sector

On the reaction day the stock moved 7.5 pts less than Nifty Microcap 250 and 6.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.1+0.4-7.5-0.3-6.8

Next day

-3.5+1.7-5.2+0.4-3.9

-3.3+0.2-3.5-0.2-3.1

-1.9+0.5-2.4-0.3-1.6

—-1.1—-1.5—

—-0.1—-0.7—

+0.1-1.6+1.8-2.6+2.8

15d

—-1.4—-4.7—

—-7.4—-8.6—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astonea Labs refiled FY25 and H2 audited results to fix a BSE filing gap (missing PDF). FY25 revenue rose 21.6 percent to Rs 9,751.83 lakh vs Rs 8,019.09 lakh. PAT grew 31.5 percent to Rs 535.05 lakh vs Rs 407.01 lakh. EPS stood at Rs 6.94 vs Rs 5.36. Some prior period figures were restated. Company debuted on BSE SME on June 3, 2025.

Likely market impact

Clean resubmission. Strong FY25 with revenue up 21.6 percent and PAT up 31.5 percent. Positive operating cash flow of Rs 924.95 lakh.